Nordic Life Science 1
TOP STORIES BUSINESS BUSINE S S D E A L THE VÄNNÄ
S-BASED COMPANY HAS BEEN ACQUIRED BY UPPSALABASED BIOTECH COMPANY OLINK PROTEOMICS. the production of polyclonal and monoclonal antibodies. Jonas Jendi, Investment Manager, Industrifonden and co-author of the report NEW RE P OR T The company provides a large range of ready-made antibodies, mainly for plant research, which are used, for example, to better understand photosynthesis. It also provides reagents and secondary antibodies, as well as custom-made antibodies for researchers and companies in various research areas, including human medicine. Agrisera and Olink have collaborated for several years, which has resulted in a strong working relationship between the two companies. THE PERIOD 2015–2019 HAS BEEN A BUSY AND EXPANSIVE ONE FOR SWEDISH LIFE SCIENCE COMPANIES, ACCORDING TO DATA ANALYZED BY INDUSTRIFONDEN. based on data and analysis, has examined the flows of capital to Therapeutics, Healthtech, Diagnostics, and Medtech companies from 2015 to 2019. The stock market represented the main source of financing, contributing 75%. Venture Capital firms contributed 7 billion SEK. New stock market listings peaked in 2017, 15 life science companies went public, raising just shy of 3.5 billion SEK of the 8.4 billion SEK raised through IPOs over the past 5 years. The number of companies listed through an IPO has since declined, with 10 IPOs in 2018 and 5 IPOs in 2019. Follow-on public offerings reached new highs in 2019, raising 7.2 billion SEK, primarily on the Nasdaq main market and First North. Therapeutics was the main area for both IPO and FPO investment over the past 5 years. Venture Capital life science funding in the Nordics was most active in Sweden (49%) and Denmark (32%), with companies raising 7 billion SEK, and just shy of 5 billion SEK, respectively. Industrifonden, Healthcap, Novo Seeds, Lundbeckfonden and Sunstone were the top five specialized life science investors in Sweden in 2018–2019. Erika Gelfgren, CEO, Agrisera 14 Following the acquisition, the plan is for Agrisera to continue operating as an independent unit without any major organizational changes. Erika Gelfgren will remain as CEO and the company will continue production from its site in Vännäs. Today Agrisera employs around 20 members of staff, but more may be recruited in the coming months. NORDICLIFESCIENCE.ORG PHOTO MARGARETA BLOM SANDBAECK